Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination drug consisting of **histamine human immunoglobulin** and **loratadine**. Loratadine is a second-generation antihistamine that acts as an inverse agonist at the histamine H1 receptor, blocking the effects of endogenous histamine and reducing symptoms of allergic rhinitis, urticaria, and other allergic dermatological conditions[3]. Loratadine additionally inhibits histamine release from human basophils[1]. Histamine human immunoglobulin is an immunoglobulin-based preparation that contains human antibodies directed at histamine; such preparations are generally used in immunomodulation and may modulate allergic or immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on histamine human immunoglobulin + loratadine.